Alnylam Pharmaceuticals has strong growth potential, particularly with Amvuttra for ATTR-CM. Read why ALNY stock justifies a ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

Good afternoon readers, and Happy Friday! We hope you had a great week. In today’s edition of Daily on Energy, Callie and ...

Halbert Hargrove executives shine a spotlight on their strategies, from market resilience and diversification to culture and advisor development.

The coworkers had to show how they pose for photos and create a love-heart symbol to see if anyone can be as cool as Gen Zers.

Following the largest domestic defense exhibit focused on the U.S. Army, Future Long Range Assault Attack (FLRAA), the ...

Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT’s ...

Cadrenal Therapeutics (Nasdaq: CVKD) announced Thursday it raised $5.1 million by selling an aggregate of 391,243 shares of ...

The FDA placed the hold on the phase 3 PRESERVE-003 trial of the antibody candidate due to varying results between patient ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Today, there’s an immunoscience renaissance happening, and Sanofi is pushing medical research in this field forward at a much ...

PETERSBURG — Members of New Life Church realize investing in their youth will help secure the future of their faith and build ...